Supplementary Materials

Jianian Hua 13#, Hezi Jiang23#, Qi Fang1,\*

1 Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu Province, China.

2 Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.

 3 Medical College of Soochow University, Suzhou 215123, PR China.

#These authors contributed equally.

\*Corresponding author
Qi Fang
fangqi\_8714@163.com

# List of Captions

|  |  |
| --- | --- |
| Table | Contents |
| Table S1 | PRISMA 2009 checklist |
| Table S2 | Characteristics of cross-sectional studies |
| Table S3 | Quality appraisal using the modified Ottawa-Newcastle Scale |
| Table S4 | Publication bias |
| Table S5 | Results of “trim and fill” |
| Figure S1 | Sensitivity analyses |

\

# Tables

## Table S1. PRISMA 2009 checklist

|  |  |  |  |
| --- | --- | --- | --- |
| **Section / topic**  | **#** | **Checklist item**  | **Reported on page #**  |
| **TITLE**  |  |
| Title  | 1 | Identify the report as a systematic review, meta-analysis, or both.  | 1 |
| **ABSTRACT**  |  |
| Structured summary  | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.  | 2 |
| **INTRODUCTION**  |  |
| Rationale  | 3 | Describe the rationale for the review in the context of what is already known.  | 3 |
| Objectives  | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  | 3 |
| **METHODS**  |  |
| Protocol and registration  | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.  | NA |
| Eligibility criteria  | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.  | 3-4 |
| Information sources  | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.  | 3 |
| Search  | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  | 3 |
| Study selection  | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).  | 3-4 |
| Data collection process  | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.  | 4 |
| Data items  | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  | 4-5 |
| Risk of bias in individual studies  | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.  | 5 |
| Summary measures  | 13 | State the principal summary measures (e.g., risk ratio, difference in means).  | 5 |
| Synthesis of results  | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.  | 5 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Section/topic**  | **#** | **Checklist item**  | **Reported on page #**  |
| Risk of bias across studies  | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).  | 5 |
| Additional analyses  | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.  | 5 |
| **RESULTS**  |  |
| Study selection  | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.  | 5, Figure 1,  |
| Study characteristics  | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.  | 5-6, Table 1, Table S2 |
| Risk of bias within studies  | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  | 5-6, Table 1, Table S2 |
| Results of individual studies  | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  | 5-6, Table 1, Table S2 |
| Synthesis of results  | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency.  | 6, Figure 2,3 |
| Risk of bias across studies  | 22 | Present results of any assessment of risk of bias across studies (see Item 15).  | 6 |
| Additional analysis  | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  | 7 |
| **DISCUSSION**  |  |
| Summary of evidence  | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).  | 7-8 |
| Limitations  | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).  | 9 |
| Conclusions  | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research.  | 9 |
| **FUNDING**  |  |
| Funding  | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  | 9 |

*From:*  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

## Table S2. Characteristics of cross-sectional studies

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, Year | Study type (follow-up time) | Country/Area, Continent | Sample size | Mean age ±SD, range | Male% | Study population | Sleep meausrement | Metabolic syndromemeasurement | Sleep(h) | Main findings reportedIn original articles: AdjustedHR/RR/OR (95% CI) |
| Santus, 2007(male)1 | Cross-sectional | PortugalEurope | 832 | 18-92 | 100 | Community | Interview | NECP ATP-III | ≤67≥9 | aOR1.40(0.76-2.60)Ref.aOR1.50(0.50-2.60) |
| Santus, 2007(female)1 | Cross-sectional | PortugalEurope | 1332 | 18-92 | 0 | Community | Interview | NECP ATP-III | ≤67≥9 | aOR0.92(0.55-1.50)Ref.aOR2.00(1.30-3.00) |
| Choi, 20082 | Cross-sectional | KoreaAsia | 4222 | 44.1±0.4≥20 | 43.2 | Community | Questionnaire | Modified NECP ATP-III | ≤57≥9 | aOR 1.17(0.87-1.59)Ref.aOR1.69 (1.17,2.45) |
| Hall, 20083 | Cross-sectional | USANorth america | 1214 | 44.4±6.830-54 | 46.6 | Community | Interview | AHA-NHLBI | <67>8 | aOR 1.76(1.13-2.74)Ref.aOR 1.69(0.91-3.00) |
| Aroar, 20114 | Cross-sectional | ChinaAsia | 29333 | 61.6±7.1>50 | 65.1 | Community | Interview | Modified NECP ATP-III | <67≥9 | aOR 0.97 (0.88-1.06)Ref.aOR 1.21(1.20-1.34) |
| Kobayashi, 20115 | Cross-sectional | JapanAsia | 44452 | 44.8±12.8 | 49.4 | Hospital | Questionnaire | Japanese criteria 2008 | <67-8≥8 | aOR 1.40 (1.21-1.60)Ref.aOR 0.98 (0.82-1.20) |
| Najafian, 20116 | Cross-sectional | IranAsia | 12322 | 38.8±14.9>19 | 48.2 | Hospital | Interview | NECP ATP-III | ≤56≥9 | aOR 1.52 (1.33-1.74)Ref.aOR 0.79 (0.68,0.94) |
| McCanlies, 20126 | Cross-sectional | USANorth America | 90 | NA | 39.6 | Company or office | Questionnaire | NECP ATP-III | <6≥6 | aOR2.30 (0.45 -6.50)Ref. |
| Sabanayagam, 20127 | Cross-sectional | USANorth America | 4307 | 44.6±0.5>20 | 49.9 | Community | Standard questionnaire | AHA-NHLBI | <57≥9 | aOR 1.24 (0.98-1.57)Ref.aOR 0.79 (0.69-1.36) |
| Wu, 2012(male)8 | Cross-sectional | TaiwanAsia | 2772 | 44.9±11.1 | 100 | Hospital | Questionnaire | Modified NECP ATP-III | <67>8 | aOR 1.28(1.01-1.63)Ref.aOR 1.43 (0.82-2.48) |

Table S2 - Continued

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, Year | Study type (follow-up time) | Country/Area, Continent | Sample size | Mean age ±SD, range | Male% | Study population | Sleep meausrement | Metabolic syndromemeasurement | Sleep(h) | Main findings reportedIn original articles: AdjustedHR/RR/OR (95% CI) |
| Wu, 2012(female)8 | Cross-sectional | TaiwanAsia | 2287 | 44.9±11.1 | 0 | Hospital | Questionnaire | Modified NECP ATP-III | <67>8 | aOR 1.04 (0.72-1.51)Ref.aOR 0.90(0.32-2.51) |
| Hung, 20139 | Cross-sectional | TaiwanAsia | 3435 | NA | 64.4 | Hospital | Standard questionnaire | AHA-NHLBI | <67-8>8 | aOR 1.02(0.56-1.48)Ref.aOR 1.56(1.38-1.74) |
| Yoo, 201310 | Cross-sectional | USANorth America | 96 | 42.4±8.3 | 0 | Company or office | Questionnaire | AHA-NHLBI | ≤67-8≥8 | aOR 2.30 (0.71–7.50)Ref.aOR 4.89 (1.32–18.13) |
| Okubo, 201411 | Cross-sectional | JapanAsia | 1481 | 57.5±14.0 |  | Community | Standard questionnaire | Japanese croteroa 2005 | <5≥6 | aOR 1.20 (0.13-10.91)Ref. |
| Saleh, 201412 | Cross-sectional | USANorth America | 1371 | 57.9±13.6≥20 | 56.0 | Community | Objective | AHA-NHLBI | <57.2-8.6≥9 | aOR 0.91 (0.62-1.33)Ref.aOR 0.95 (0.66-1.39) |
| Yu, 2014(male)13 | Cross-sectional | ChinaAsia | 1618 | 54.4±10.8≥35 | 100 | Community | Questionnaire | Modified NECP ATP-III | ≤77-8>9 | aOR 0.95 (0.83-1.10)Ref.aOR 1.17(0.82-1.67) |
| Yu, 2014(female)13 | Cross-sectional | ChinaAsia | 4488 | 53.4±10.3≥35 | 0 | Community | Questionnaire | Modified NECP ATP-III | ≤77-8>9 | aOR 0.99(0.90-1.09)Ref.aOR 1.17(0.92-1.49) |
| Canuto, 201514 | Cross-sectional | BrazilSouth America | 902 | 31.0±8.7 | 34.1 | Company or office | Questionnaire | AHA-NHLBI | <5≥5 | aOR 1.70 (1.09-2.24)Ref. |
| Chang, 201515 | Cross-sectional | TaiwanAsia | 796 | 37.1±7.620-60 | 100 | Company or office | Standard questionnaire | AHA-NHLBI | <57-8≥8 | aOR 1.04 (0.51-2.13)Ref.aOR 1.44 (0.69-2.98) |
| Wu, 2015(male)16 | Cross-sectional | ChinaAsia | 11380 | 63.6±7.7 | 100 | Company or office | Questionnaire | IDF | <77-8≥10 | aOR 1.04 (0.93-1.17)Ref.aOR 1.01 (0.94-1.10) |

Table S2 - Continued

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, Year | Study type (follow-up time) | Country/Area, Continent | Sample size | Mean age ±SD, range | Male% | Study population | Sleep meausrement | Metabolic syndromemeasurement | Sleep(h) | Main findings reportedIn original articles: AdjustedHR/RR/OR (95% CI) |
| Wu, 2015(female)16 | Cross-sectional | ChinaAsia | 13804 | 63.6±7.7 | 0 | Company or office | Questionnaire | IDF | <77-8≥10 | aOR 0.93 (0.79-1.10)Ref.aOR 1.10 (0.97-1.24) |
| Lin, 201617 | Cross-sectional | TaiwanAsia | 4197 | NA | 46.0 | Community | Questionnaire | IDF | <77-8≥9 | aOR 1.54 (1.05–2.47) Ref.aOR 1.12 (0.70–1.82)  |
| Min, 201618 | Cross-sectional | KoreaAsia | 8558 | 20-75 | 0 | Community | Questionnaire | NECP ATP-III | ≤57≥9 | aOR 0.75 (0.59–0.85)Ref.aOR 0.83 (0.68–1.02) |
| Xiao, 2016(male)19 | Cross-sectional | ChinaAsia | 13505 | 18-74 | 100 | Community | Questionnaire | IDF | ≤7>8 | Ref.aOR 1.20(0.95–1.52) |
| Xiao, 2016(female)19 | Cross-sectional | ChinaAsia | 6977 | 18-74 | 0 | Community | Questionnaire | IDF | ≤7>8 | Ref.aOR 1.16(1.00–1.35)  |
| Cole,201720 | Cross-sectional | ChanaAfrica | 263 | 46.0±11.6 | 41.0 | Community | Objective | AHA-NHLBI | <77-8>8 | aOR 0.96(0.39-1.38)Ref.aOR 1.98 (0.92-4.26) |
| Suliga, 2017(male)21 | Cross-sectional | PolishEurope | 3056 | 37-66 | 100 | Community | Questionnaire | NECP ATP-III | ≤67-8≥9 | aOR 0.99 (0.91–1.07)Ref.aOR 1.14 (0.97–1.35) |
| Suliga, 2017(female)21 | Cross-sectional | PolishEurope | 7311 | 37-66 | 0 | Community | Questionnaire | NECP ATP-III | ≤67-8≥9 | aOR 1.00 (0.94–1.07) Ref.aOR 1.05 (0.95–1.16) |
| Kaira, 201822 | Cross-sectional | DutchEurope | 1679 | 60.8±6.440-75 | 47.4 | Community | Standard questionnaire | NECP ATP-III | <77-8≥9 | aOR 0.96 (0.7-1.3)Ref.aOR 0.85 (0.6-1.2) |
| Kim, 2018(male)23 | Cross-sectional | KoreaAsia | 44930 | 40-69 | 100 | Community | Interview | NECP ATP-III | <66-88-10 | aOR 1.12 (1.05–1.19) Ref.aOR 1.01 (0.96–1.06) |

Table S2 - Continued

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author, Year | Study type (follow-up time) | Country/Area, Continent | Sample size | Mean age ±SD, range | Male% | Study population | Sleep meausrement | Metabolic syndromemeasurement | Sleep(h) | Main findings reportedIn original articles: AdjustedHR/RR/OR (95% CI) |
| Kim, 2018(female)23 | Cross-sectional | KoreaAsia | 88678 | 40-69 | 0 | Community | Interview | NECP ATP-III | <66-88-10 | aOR 1.05 (1.00–1.10) Ref,aOR 1.08 (1.04–1.12) |
| Ostadrahimi, 201824 | Cross-sectional | IranAsia | 14916 | 35-70 | 50.0 | Community | Standard questionnaire | NECP ATP-III | <66-9>9 | aOR 0.97 (0.85-1.10)Ref.aOR 1.18(1.05-1.33) |
| Titova, 201825 | Cross-sectional | SwedenEurope | 19691 | 60.4±8.5 | 44.0 | Community | Interview | AHA-NHLBI | ≤67-8≥9 | aOR 1.08 (1.03–1.13)Ref.aOR 1.26(1.14–1.39) |
| Qian, 201926 | Cross-sectional | ChinaAsia | 4579 | 67.6±6.3>60 |  | Community | Questionnaire | NECP ATP-III | <77-88-9 | aOR 1.59 (1.10–2.33)Ref.aOR 1.42 (1.10–1.82) |

## Table S3. Quality appraisal using the modified Ottawa-Newcastle Scale

|  |  |  |
| --- | --- | --- |
| Author, year | Design | Ottawa-Newcastle Scale |
|  |  | Selection | Comparability | Exposure/outcome |
| Choi, 2011(male) | Prospective cohort | ★★★★ | ★★ | ★★★ |
| Choi, 2011(female) | PC | ★★★★ | ★★ | ★★★ |
| Otsuka, 2011 | PC | ★★★ | ★ | ★★★ |
| Chaput, 2013 | PC | ★★★ | ★ | ★★★ |
| Kim, 2015 | PC | ★★★ | ★★ | ★★ |
| Li, 2015(male) | PC | ★★★★ | ★★ | ★★★ |
| Li, 2015(female) | PC | ★★★★ | ★★ | ★★★ |
| Song, 2016 | PC | ★★★ | ★★ | ★★ |
| Deng, 2017 | PC | ★★★★ | ★★ | ★★★ |
| Itani, 2017 | PC | ★★★★ | ★ | ★★★ |
| Yingnan, 2020 | PC | ★★★ | ★★ | ★★★ |
|  |  | Modiefied Ottawa-Newcastle Scale |
| Santus, 2007(male) | C-S | ★★★ | ★★ | ★★ |
| Santus, 2007(female) | C-S | ★★★ | ★★ | ★★ |
| Choi, 2008 | C-S | ★★★ | ★★ | ★★ |
| Hall, 2008 | C-S | ★★★ | ★★ | ★★ |
| Aroar, 2011 | C-S | ★★★ | ★★ | ★★ |
| Kobayashi, 2011 | C-S | ★★ | ★★ | ★★ |
| Najafian, 2011 | C-S | ★★ | ★ | ★★ |
| McCanlies, 2012 | C-S | ★★ | ★ | ★★ |
| Sabanayagam, 2012 | C-S | ★★★ | ★★ | ★★ |
| Wu, 2012(male) | C-S | ★★★ | ★★ | ★★ |
| Wu, 2012(female) | C-S | ★★★ | ★★ | ★★ |
| Hung, 2013 | C-S | ★★ | ★★ | ★★ |
| Yoo, 2013 | C-S | ★★ | ★★ | ★★ |
| Okubo, 2014 | C-S | ★★★ | ★ | ★★ |
| Saleh, 2014 | C-S | ★★★ | ★★ | ★★★ |
| Yu, 2014(male) | C-S | ★★★ | ★★ | ★★ |
| Yu, 2014(female) | C-S | ★★★ | ★★ | ★★ |

Table S3 - Continued

|  |  |  |
| --- | --- | --- |
| Author, year | Design | Modiefied Ottawa-Newcastle Scale |
|  |  | Selection | Comparability | Exposure/outcome |
| Canuto, 2015 | C-S | ★★ | ★ | ★★ |
| Chang, 2015 | C-S | ★★★ | ★★ | ★★ |
| Wu, 2015(male) | C-S | ★★★ | ★★ | ★★ |
| Wu, 2015(female) | C-S | ★★★ | ★★ | ★★ |
| Lin, 2016 | C-S | ★★★ | ★★ | ★★ |
| Min, 2016 | C-S | ★★★★ | ★★ | ★★ |
| Xiao, 2016(male) | C-S | ★★★ | ★ | ★★ |
| Xiao, 2016(female) | C-S | ★★★ | ★ | ★★ |
| Cole,2017 | C-S | ★★★ | ★★ | ★★★ |
| Suliga, 2017(male) | C-S | ★★★★ | ★★ | ★★ |
| Suliga, 2017(female) | C-S | ★★★★ | ★★ | ★★ |
| Kaira, 2018 | C-S | ★★★ | ★★ | ★★ |
| Kim, 2018(male) | C-S | ★★★★ | ★★ | ★★ |
| Kim, 2018(female) | C-S | ★★★★ | ★★ | ★★ |
| Ostadrahimi, 2018 | C-S | ★★★ | ★★ | ★★ |
| Titova, 2018 | C-S | ★★★ | ★★ | ★★ |
| Qian, 2019 | C-S | ★★★ | ★★ | ★★ |

Abbreviations: PC, prospective cohort study; C-S, cross-sectional study.

## Table S4. Publication bias

|  |  |  |
| --- | --- | --- |
|  | P for Egger test | P for Begg test |
| Short, cohort | 0.077 | 0.312 |
| Long, cohort | 0.213 | 0.140 |
| Short, cross-sectional | 0.373 | 0.345 |
| Long, cross-sectional | 0.219 | 0.153 |

## Table S5. Results of “trim and fill”

|  |  |  |
| --- | --- | --- |
|  | Corrected estimate~~a~~ | Original estimate |
| Short, cohort | 1.22 (1.15, 1.29) | 1.15 (1.05, 1.15) |
| Long, cohort | 0.96 (0.86, 1.07) | 1.02 (0.85, 1.18) |
| Short, cross-sectional | 1.07 (1.04, 1.10) | 1.12 (1.08, 1.18) |
| Long, cross-sectional | 1.10 (1.07, 1.13) | 1.11 (1.04, 1.17) |

~~a~~The effect estimate after “trim and fill” correction.

# Figure legends

Figure S1. Sensitive analyses. Sensitivity analyses of association between sleep duration and metabolic syndrome by omitting one study each time and rerunning the analyses. (A) short sleep duration among cohort studies; (B) long sleep duration among cohort studies; (C) short sleep duration among cross-sectional studies; (D) long sleep duration among cross-sectional studies.

# References for Supplementary Tables

1. Santos AC, Ebrahim S, Barros H. Alcohol intake, smoking, sleeping hours, physical activity and the metabolic syndrome. *Prev Med* 2007; **44**(4): 328-34.

2. Choi KM, Lee JS, Park HS, Baik SH, Choi DS, Kim SM. Relationship between sleep duration and the metabolic syndrome: Korean National Health and Nutrition Survey 2001. *Int J Obes (Lond)* 2008; **32**(7): 1091-7.

3. Hall MH, Muldoon MF, Jennings JR, Buysse DJ, Flory JD, Manuck SB. Self-reported sleep duration is associated with the metabolic syndrome in midlife adults. *Sleep* 2008; **31**(5): 635-43.

4. Arora T, Jiang CQ, Thomas GN, et al. Self-reported long total sleep duration is associated with metabolic syndrome: the Guangzhou Biobank Cohort Study. *Diabetes Care* 2011; **34**(10): 2317-9.

5. Kobayashi D, Takahashi O, Deshpande GA, Shimbo T, Fukui T. Relation between metabolic syndrome and sleep duration in Japan: a large scale cross-sectional study. *Intern Med* 2011; **50**(2): 103-7.

6. Najafian J, Toghianifar N, Mohammadifard N, Nouri F. Association between sleep duration and metabolic syndrome in a population-based study: Isfahan Healthy Heart Program. *J Res Med Sci* 2011; **16**(6): 801-6.

7. Sabanayagam C, Zhang R, Shankar A. Markers of Sleep-Disordered Breathing and Metabolic Syndrome in a Multiethnic Sample of US Adults: Results from the National Health and Nutrition Examination Survey 2005-2008. *Cardiol Res Pract* 2012; **2012**: 630802.

8. Wu MC, Yang YC, Wu JS, Wang RH, Lu FH, Chang CJ. Short sleep duration associated with a higher prevalence of metabolic syndrome in an apparently healthy population. *Prev Med* 2012; **55**(4): 305-9.

9. Hung HC, Yang YC, Ou HY, Wu JS, Lu FH, Chang CJ. The association between self-reported sleep quality and metabolic syndrome. *PLoS One* 2013; **8**(1): e54304.

10. Yoo H, Franke WD. Sleep habits, mental health, and the metabolic syndrome in law enforcement officers. *J Occup Environ Med* 2013; **55**(1): 99-103.

11. Okubo N, Matsuzaka M, Takahashi I, et al. Relationship between self-reported sleep quality and metabolic syndrome in general population. *BMC Public Health* 2014; **14**: 562.

12. Saleh D, Janssen I. Interrelationships among sedentary time, sleep duration, and the metabolic syndrome in adults. *BMC Public Health* 2014; **14**: 666.

13. Yu S, Guo X, Yang H, Zheng L, Sun Y. An update on the prevalence of metabolic syndrome and its associated factors in rural northeast China. *BMC Public Health* 2014; **14**: 877.

14. Canuto R, Pattussi MP, Macagnan JB, Henn RL, Olinto MT. Metabolic syndrome in fixed-shift workers. *Rev Saude Publica* 2015; **49**: 30.

15. Chang JH, Huang PT, Lin YK, et al. Association between sleep duration and sleep quality, and metabolic syndrome in Taiwanese police officers. *Int J Occup Med Environ Health* 2015; **28**(6): 1011-23.

16. Wu J, Xu G, Shen L, et al. Daily sleep duration and risk of metabolic syndrome among middle-aged and older Chinese adults: cross-sectional evidence from the Dongfeng-Tongji cohort study. *BMC Public Health* 2015; **15**: 178.

17. Lin SC, Sun CA, You SL, et al. The Link of Self-Reported Insomnia Symptoms and Sleep Duration with Metabolic Syndrome: A Chinese Population-Based Study. *Sleep* 2016; **39**(6): 1261-6.

18. Min H, Um YJ, Jang BS, et al. Association between Sleep Duration and Measurable Cardiometabolic Risk Factors in Healthy Korean Women: The Fourth and Fifth Korean National Health and Nutrition Examination Surveys (KNHANES IV and V). *Int J Endocrinol* 2016; **2016**: 3784210.

19. Xiao J, Shen C, Chu MJ, et al. Physical Activity and Sedentary Behavior Associated with Components of Metabolic Syndrome among People in Rural China. *PLoS One* 2016; **11**(1): e0147062.

20. Cole HV, Owusu-Dabo E, Iwelunmor J, et al. Sleep duration is associated with increased risk for cardiovascular outcomes: a pilot study in a sample of community dwelling adults in Ghana. *Sleep Med* 2017; **34**: 118-25.

21. Suliga E, Koziel D, Ciesla E, Rebak D, Gluszek S. Sleep duration and the risk of metabolic syndrome-A cross-sectional study. 2017.

22. van der Pal KC, Koopman ADM, Lakerveld J, et al. The association between multiple sleep-related characteristics and the metabolic syndrome in the general population: the New Hoorn study. *Sleep Med* 2018; **52**: 51-7.

23. Kim CE, Shin S, Lee HW, et al. Association between sleep duration and metabolic syndrome: a cross-sectional study. *BMC Public Health* 2018; **18**(1): 720.

24. Ostadrahimi A, Nikniaz Z, Faramarzi E, Mohammadpoorasl A, Ansarin K, Somi MH. Does long sleep duration increase risk of metabolic syndrome in Azar cohort study population? *Health Promot Perspect* 2018; **8**(4): 290-5.

25. Titova OE, Lindberg E, Elmstahl S, Lind L, Schioth HB, Benedict C. Associations Between the Prevalence of Metabolic Syndrome and Sleep Parameters Vary by Age. *Front Endocrinol (Lausanne)* 2018; **9**: 234.

26. Qian YX, Liu JH, Ma QH, Sun HP, Xu Y, Pan CW. Associations of sleep durations and sleep-related parameters with metabolic syndrome among older Chinese adults. *Endocrine* 2019; **66**(2): 240-8.